5HT-2 receptor and fluvoxamine effect in Obsessive-Compulsive Disorder

S. Erzegovesi, P. Ronchi, E. Smeraldi

Research output: Contribution to journalArticle

Abstract

The aim of the study was to test the role of the 5HT-2 receptor in the antiobsessional effect of 5HT uptake inhibitors. For this purpose we designed a double blind controlled clinical trial, in which ritanserin (a specific 5HT-2 receptor antagonist) or placebo were administered to a sample of 10 patients affected by Obsessive Compulsive Disorder (OCD), symptomatologically stabilized during fluvoxamine monotherapy. In order to quantify OCD symptom severity we used the Yale Brown Obsessive Compulsive Scale (Y-BOCS), administered weekly for the 14 days of the study. One way Analysis of Variance (ANOVA), performed on Y-BOCS total scores, showed a significant difference between the two treatment groups. The difference between ritanserin and placebo effect seemed to be related either to the slight worsening of the ritanserin group, or to the improvement in the placebo one. These results suggest that 5HT-2 receptor may be involved in the antiobsessional effect of fluvoxamine.

Original languageEnglish
Pages (from-to)287-289
Number of pages3
JournalHuman Psychopharmacology
Volume7
Issue number4
DOIs
Publication statusPublished - 1992

Fingerprint

Ritanserin
Fluvoxamine
Obsessive-Compulsive Disorder
Placebos
Placebo Effect
Controlled Clinical Trials
Analysis of Variance
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

5HT-2 receptor and fluvoxamine effect in Obsessive-Compulsive Disorder. / Erzegovesi, S.; Ronchi, P.; Smeraldi, E.

In: Human Psychopharmacology, Vol. 7, No. 4, 1992, p. 287-289.

Research output: Contribution to journalArticle

Erzegovesi, S. ; Ronchi, P. ; Smeraldi, E. / 5HT-2 receptor and fluvoxamine effect in Obsessive-Compulsive Disorder. In: Human Psychopharmacology. 1992 ; Vol. 7, No. 4. pp. 287-289.
@article{213bf947ebe2417ba17a7893786f62a7,
title = "5HT-2 receptor and fluvoxamine effect in Obsessive-Compulsive Disorder",
abstract = "The aim of the study was to test the role of the 5HT-2 receptor in the antiobsessional effect of 5HT uptake inhibitors. For this purpose we designed a double blind controlled clinical trial, in which ritanserin (a specific 5HT-2 receptor antagonist) or placebo were administered to a sample of 10 patients affected by Obsessive Compulsive Disorder (OCD), symptomatologically stabilized during fluvoxamine monotherapy. In order to quantify OCD symptom severity we used the Yale Brown Obsessive Compulsive Scale (Y-BOCS), administered weekly for the 14 days of the study. One way Analysis of Variance (ANOVA), performed on Y-BOCS total scores, showed a significant difference between the two treatment groups. The difference between ritanserin and placebo effect seemed to be related either to the slight worsening of the ritanserin group, or to the improvement in the placebo one. These results suggest that 5HT-2 receptor may be involved in the antiobsessional effect of fluvoxamine.",
author = "S. Erzegovesi and P. Ronchi and E. Smeraldi",
year = "1992",
doi = "10.1002/hup.470070409",
language = "English",
volume = "7",
pages = "287--289",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - 5HT-2 receptor and fluvoxamine effect in Obsessive-Compulsive Disorder

AU - Erzegovesi, S.

AU - Ronchi, P.

AU - Smeraldi, E.

PY - 1992

Y1 - 1992

N2 - The aim of the study was to test the role of the 5HT-2 receptor in the antiobsessional effect of 5HT uptake inhibitors. For this purpose we designed a double blind controlled clinical trial, in which ritanserin (a specific 5HT-2 receptor antagonist) or placebo were administered to a sample of 10 patients affected by Obsessive Compulsive Disorder (OCD), symptomatologically stabilized during fluvoxamine monotherapy. In order to quantify OCD symptom severity we used the Yale Brown Obsessive Compulsive Scale (Y-BOCS), administered weekly for the 14 days of the study. One way Analysis of Variance (ANOVA), performed on Y-BOCS total scores, showed a significant difference between the two treatment groups. The difference between ritanserin and placebo effect seemed to be related either to the slight worsening of the ritanserin group, or to the improvement in the placebo one. These results suggest that 5HT-2 receptor may be involved in the antiobsessional effect of fluvoxamine.

AB - The aim of the study was to test the role of the 5HT-2 receptor in the antiobsessional effect of 5HT uptake inhibitors. For this purpose we designed a double blind controlled clinical trial, in which ritanserin (a specific 5HT-2 receptor antagonist) or placebo were administered to a sample of 10 patients affected by Obsessive Compulsive Disorder (OCD), symptomatologically stabilized during fluvoxamine monotherapy. In order to quantify OCD symptom severity we used the Yale Brown Obsessive Compulsive Scale (Y-BOCS), administered weekly for the 14 days of the study. One way Analysis of Variance (ANOVA), performed on Y-BOCS total scores, showed a significant difference between the two treatment groups. The difference between ritanserin and placebo effect seemed to be related either to the slight worsening of the ritanserin group, or to the improvement in the placebo one. These results suggest that 5HT-2 receptor may be involved in the antiobsessional effect of fluvoxamine.

UR - http://www.scopus.com/inward/record.url?scp=0026484375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026484375&partnerID=8YFLogxK

U2 - 10.1002/hup.470070409

DO - 10.1002/hup.470070409

M3 - Article

AN - SCOPUS:0026484375

VL - 7

SP - 287

EP - 289

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 4

ER -